COPD and asthma devices market seen reaching $62.83 billion by 2030

The market for chronic obstructive pulmonary disease and asthma devices is projected to grow from $47.56 billion in 2025 to $50.3 billion in 2026, according to The Business Research Company. Rising respiratory disease rates, pollution and smoking are driving demand, with North America holding the largest regional share in 2025.

Why it matters: - COPD and asthma devices are becoming more important as respiratory disease rates climb worldwide. - The market’s growth points to rising demand for inhalers, home-based respiratory devices and broader respiratory care services. - The expansion also reflects a shift toward earlier diagnosis and longer-term chronic disease management.

What happened: - The Business Research Company released its "Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - The report projects the market will grow from $47.56 billion in 2025 to $50.3 billion in 2026. - The report forecasts the market will reach $62.83 billion by 2030. - North America held the largest share of the market in 2025.

The details: - The report puts the 2025-2026 growth rate at 5.8% CAGR. - It projects 5.7% CAGR growth through 2030. - The report links recent growth to higher asthma and COPD prevalence, rising air pollution, smoking rates, wider use of inhalation therapies, growth in respiratory care services and better diagnosis of chronic respiratory disease. - The forecast through 2030 is tied to an aging population, stronger demand for home-based respiratory devices, more awareness of early respiratory disease management, expanded chronic disease management programs and better access to respiratory care in emerging markets. - The report says the respiratory disease market includes asthma, COPD, pneumonia, lung cancer and other conditions that affect lung function and breathing. - The report cites a December 2023 forecast from the US National Center for Biotechnology Information that global COPD cases could rise by 112 million to 592 million by 2050, or 9.5% of the global eligible population. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies, future trends, updated graphics and tables. - The company also offered a free sample report and the full market report.

Between the lines: - The report frames respiratory care as a long-duration growth market, not a short-term spike. - The combination of aging populations, environmental exposure and chronic disease management suggests steady device demand across developed and emerging markets. - The North America lead indicates that advanced care adoption remains strongest in mature healthcare systems, even as emerging markets become more relevant to future growth.

What's next: - The market is expected to keep expanding through 2030 as home care, early intervention and chronic disease programs gain traction. - Access to respiratory care in emerging markets could become a bigger growth driver if infrastructure and diagnosis rates continue improving. - The business outlook will likely track broader trends in pollution, smoking, aging and respiratory disease prevalence.

The bottom line: - COPD and asthma devices remain a steady-growth market, with rising disease burden and home-care demand supporting a projected climb to $62.83 billion by 2030.